Vaxcyte Reports $320.6 Million Net Loss and Expands Clinical Programs in Latest 10-Q Filing

Vaxcyte, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $320.6 million, a substantial increase of 127.8% compared to a net loss of $140.7 million in the same period last year. This increase in losses was primarily driven by a 111.1% rise in research and development expenses, which totaled $312.8 million, up from $148.1 million in the prior year. The surge in expenses was largely attributed to heightened manufacturing and clinical trial activities related to its pneumococcal conjugate vaccine (PCV) programs.

In terms of liquidity, Vaxcyte reported cash and cash equivalents of $260.8 million and short-term investments of $1.5 billion as of March 31, 2026, compared to $174.0 million and $1.4 billion, respectively, at the end of 2025. The company’s total assets increased to $3.35 billion, up from $3.00 billion at the end of the previous fiscal year. This growth in assets was accompanied by a rise in total liabilities, which reached $352.3 million, up from $317.2 million, reflecting increased operational commitments.

Strategically, Vaxcyte has made notable advancements in its clinical programs, particularly with its lead candidate, VAX-31. The company completed enrollment in several Phase 3 trials, including OPUS-1, OPUS-2, and OPUS-3, which are pivotal for evaluating the safety and efficacy of VAX-31 in adults and children. Additionally, Vaxcyte has expanded its manufacturing capabilities through agreements with Lonza and Thermo Fisher Scientific, aimed at supporting the anticipated commercial launch of its vaccine candidates.

Operationally, Vaxcyte's workforce has grown, with an increase in employee headcount to support its expanding clinical and manufacturing activities. The company is also focused on enhancing its infrastructure, including the establishment of a dedicated facility in North Carolina for vaccine production. Despite the current financial losses, Vaxcyte maintains a positive outlook, projecting that its existing cash and investments will be sufficient to fund operations for at least the next 12 months. The company continues to seek additional funding avenues to support its ongoing research and development efforts, as well as potential commercialization of its vaccine candidates.